Key result
Untreated RA links to ~19% higher serum adenosine deaminase activity compared to healthy controls.
Why the study?
The study aimed to determine the catalytic activities of ADA isoenzymes in serum of RA patients with and without methotrexate treatment and to evaluate their diagnostic and monitoring potential.
Can serum ADA, ADA1, and ADA2 isoenzyme catalytic activities be used to diagnose and monitor treatment effects in patients with rheumatoid arthritis?
Cross-Sectional (n=120)
Can serum ADA, ADA1, and ADA2 isoenzyme catalytic activities be used to diagnose and monitor treatment effects in patients with rheumatoid arthritis?
Serum ADA1 and ADA2 isoenzyme activities may serve as useful biochemical markers for diagnosing rheumatoid arthritis and monitoring the effects of methotrexate therapy.
Serum ADA activities may support RA diagnosis and methotrexate monitoring; hypothesis-generating, requires prospective validation before clinical use.
Adenosine Deaminase Isoenzymes in the Diagnosis and Monitoring of Rheumatoid Arthritis The aim of this study was determination of the catalytic activities of adenosine deaminase (ADA), ADA1 and ADA2 isoenzymes in the serum of patients suffering from rheumatoid arthritis (RA) who were and were not treated with methotrexate (MTX), and identification of the possibilities of using these biochemical parameters in diagnosing and monitoring the treatment effects in RA. Catalytic activities of total ADA (tADA) and ADA2 in serum were determined by a spectrophotometric method. A statistically significant correlation was found between the total ADA and ADA1 values, as well as between tADA and ADA2 in the serum of all patients suffering from RA. Determination of ADA1 and ADA2 isoenzyme catalytic activities in the serum of patients who might be suffering from RA improves the diagnostic value of total ADA catalytic activity determination. ADA2 catalytic activity in serum can be a useful biochemical marker in diagnosing and monitoring RA. Decrease in ADA1 isoenzyme catalytic activities in the serum of patients suffering from RA who were treated with MTX can help in the observation of MTX therapy effects.
No takes yet. Share an insight, caveat, or question.
Nalesnik et al. (2012) conducted a cross-sectional in Rheumatoid arthritis (n=120). Methotrexate treatment vs. Untreated rheumatoid arthritis patients and healthy controls was evaluated on Serum total adenosine deaminase (tADA) catalytic activity in untreated RA patients vs healthy controls (p=<0.001). Untreated rheumatoid arthritis patients had significantly higher serum catalytic activities of total adenosine deaminase (23.37 U/L) compared to healthy controls (19.65 U/L, p<0.001), while methotrexate-treated patients showed significantly lower activities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: